Skip to main content

07-06-2022 | EULAR 2022 | Conference coverage | Video

The BE COMPLETE and BE OPTIMAL trials of bimekizumab in PsA

Joseph Merola talks about the BE COMPLETE and BE OPTIMAL trials, which showed that the dual IL-17A/IL-17F inhibitor bimekizumab is a promising treatment option for psoriatic arthritis patients with and without prior exposure to TNF inhibitors (6:27).

00:00 Background to the studies 

01:42 Key findings from BE OPTIMAL 

02:59 Key findings from BE COMPLETE 

04:22 How the results compare 

04:43 Bimekizumab safety 

04:55 Relevance for clinical practice